Halozyme Therapeutics, Inc. NASDAQ:HALO

Halozyme Therapeutics stock price today

$70
+21.86
+45.44%
Financial Health
0
1
2
3
4
5
6
7
8
9

Halozyme Therapeutics stock price monthly change

-9.50%
month

Halozyme Therapeutics stock price quarterly change

-9.50%
quarter

Halozyme Therapeutics stock price yearly change

+30.43%
year

Halozyme Therapeutics key metrics

Market Cap
5.94B
Enterprise value
6.24B
P/E
24.82
EV/Sales
9.45
EV/EBITDA
19.78
Price/Sales
7.52
Price/Book
29.27
PEG ratio
-0.51
EPS
2.46
Revenue
862.98M
EBITDA
461.18M
Income
318.80M
Revenue Q/Q
20.80%
Revenue Y/Y
22.41%
Profit margin
30.62%
Oper. margin
40.53%
Gross margin
78.9%
EBIT margin
40.53%
EBITDA margin
53.44%
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Halozyme Therapeutics stock price history

Halozyme Therapeutics stock forecast

Halozyme Therapeutics financial statements

Average Price Target
Last Year

$52

Potential downside: -25.71%

Based on estimate of 1 analysts
  • Analysts Price target

  • Financials & Ratios estimates

Halozyme Therapeutics, Inc. (NASDAQ:HALO): Profit margin
Jun 2023 221.03M 74.75M 33.82%
Sep 2023 216.03M 81.83M 37.88%
Dec 2023 230.03M 85.38M 37.12%
Mar 2024 195.87M 76.82M 39.22%
Halozyme Therapeutics, Inc. (NASDAQ:HALO): Debt to assets
Jun 2023 1810440000 1.65B 91.66%
Sep 2023 1892662000 1.64B 86.83%
Dec 2023 1733270000 1.64B 95.16%
Mar 2024 1841527000 1.66B 90.34%
Halozyme Therapeutics, Inc. (NASDAQ:HALO): Cash Flow
Jun 2023 66.84M 54.99M 2.44M
Sep 2023 132.41M -83.45M 4.10M
Dec 2023 102.35M -8.29M -249.92M
Mar 2024 129.42M -82.68M -489K

Halozyme Therapeutics alternative data

Halozyme Therapeutics, Inc. (NASDAQ:HALO): Employee count
Aug 2023 393
Sep 2023 393
Oct 2023 393
Nov 2023 393
Dec 2023 393
Jan 2024 393
Feb 2024 393
Mar 2024 373
Apr 2024 373
May 2024 373
Jun 2024 373
Jul 2024 373

Halozyme Therapeutics other data

85.16% -1.74%
of HALO is owned by hedge funds
125.01M -2.45M
shares is hold by hedge funds

Halozyme Therapeutics, Inc. (NASDAQ:HALO): Insider trades (number of shares)
Period Buy Sel
Nov 2023 0 11708
Dec 2023 0 20000
Jan 2024 0 10000
Feb 2024 0 20000
Mar 2024 0 20000
Apr 2024 0 20000
May 2024 0 20000
Jun 2024 0 60000
Jul 2024 0 25000
Aug 2024 0 79881
Sep 2024 0 80000
Oct 2024 0 40000
Transaction Date Insider Security Shares Price per share Total value Source
Option
LABARRE MICHAEL J. officer: SVP, CHI.. Common Stock 10,000 $19.98 $199,800
Option
LABARRE MICHAEL J. officer: SVP, CHI.. Common Stock 10,000 $19.98 $199,800
Sale
LABARRE MICHAEL J. officer: SVP, CHI.. Common Stock 10,000 $53.26 $532,590
Sale
LABARRE MICHAEL J. officer: SVP, CHI.. Common Stock 10,000 $53.26 $532,590
Option
LABARRE MICHAEL J. officer: SVP, CHI.. Option to Purchase Common Stock 10,000 $19.98 $199,800
Option
LABARRE MICHAEL J. officer: SVP, CHI.. Option to Purchase Common Stock 10,000 $19.98 $199,800
Option
LABARRE MICHAEL J. officer: SVP, CHI.. Common Stock 5,509 $16.65 $91,725
Option
LABARRE MICHAEL J. officer: SVP, CHI.. Common Stock 5,509 $16.65 $91,725
Sale
LABARRE MICHAEL J. officer: SVP, CHI.. Common Stock 9,923 $53.74 $533,292
Sale
LABARRE MICHAEL J. officer: SVP, CHI.. Common Stock 9,923 $53.74 $533,292
Insider Compensation
Dr. Helen I. Torley M.B. Ch. B., M.R.C.P. (1963) Pres, Chief Executive Officer & Director
$1,520,000
Ms. Elaine D. Sun (1972) Senior Vice President & Chief Financial Officer $859,580
Dr. Michael J. LaBarre (1964) Senior Vice President & Chief Technical Officer $710,180
Monday, 23 December 2024
zacks.com
zacks.com
Monday, 16 December 2024
zacks.com
Wednesday, 11 December 2024
zacks.com
Monday, 9 December 2024
zacks.com
zacks.com
Thursday, 5 December 2024
zacks.com
zacks.com
zacks.com
Wednesday, 27 November 2024
prnewswire.com
Monday, 25 November 2024
zacks.com
Friday, 22 November 2024
zacks.com
zacks.com
reuters.com
prnewswire.com
Thursday, 21 November 2024
zacks.com
Tuesday, 19 November 2024
zacks.com
zacks.com
zacks.com
Monday, 18 November 2024
youtube.com
marketwatch.com
prnewswire.com
Friday, 15 November 2024
benzinga.com
zacks.com
Thursday, 14 November 2024
prnewswire.com
reuters.com
Tuesday, 5 November 2024
seekingalpha.com
Monday, 4 November 2024
zacks.com
Friday, 1 November 2024
fxempire.com
zacks.com
  • What's the price of Halozyme Therapeutics stock today?

    One share of Halozyme Therapeutics stock can currently be purchased for approximately $70.

  • When is Halozyme Therapeutics's next earnings date?

    Unfortunately, Halozyme Therapeutics's (HALO) next earnings date is currently unknown.

  • Does Halozyme Therapeutics pay dividends?

    No, Halozyme Therapeutics does not pay dividends.

  • How much money does Halozyme Therapeutics make?

    Halozyme Therapeutics has a market capitalization of 5.94B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 25.62% to 829.25M US dollars.

  • What is Halozyme Therapeutics's stock symbol?

    Halozyme Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "HALO".

  • What is Halozyme Therapeutics's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Halozyme Therapeutics?

    Shares of Halozyme Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Halozyme Therapeutics's key executives?

    Halozyme Therapeutics's management team includes the following people:

    • Dr. Helen I. Torley M.B. Ch. B., M.R.C.P. Pres, Chief Executive Officer & Director(age: 62, pay: $1,520,000)
    • Ms. Elaine D. Sun Senior Vice President & Chief Financial Officer(age: 53, pay: $859,580)
    • Dr. Michael J. LaBarre Senior Vice President & Chief Technical Officer(age: 61, pay: $710,180)
  • How many employees does Halozyme Therapeutics have?

    As Jul 2024, Halozyme Therapeutics employs 373 workers.

  • When Halozyme Therapeutics went public?

    Halozyme Therapeutics, Inc. is publicly traded company for more then 21 years since IPO on 16 Mar 2004.

  • What is Halozyme Therapeutics's official website?

    The official website for Halozyme Therapeutics is halozyme.com.

  • Where are Halozyme Therapeutics's headquarters?

    Halozyme Therapeutics is headquartered at 11388 Sorrento Valley Road, San Diego, CA.

  • How can i contact Halozyme Therapeutics?

    Halozyme Therapeutics's mailing address is 11388 Sorrento Valley Road, San Diego, CA and company can be reached via phone at 858 794 8889.

  • What is Halozyme Therapeutics stock forecast & price target?

    Based on 1 Wall Street analysts` predicted price targets for Halozyme Therapeutics in the last 12 months, the avarage price target is $52. The average price target represents a -25.71% change from the last price of $70.

Halozyme Therapeutics company profile:

Halozyme Therapeutics, Inc.

halozyme.com
Exchange:

NASDAQ

Full time employees:

373

Industry:

Biotechnology

Sector:

Healthcare

Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its flagship product is Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in subcutaneous urography and to improve resorption of radiopaque agents. The company also develops Perjeta; RITUXAN HYCELA and MabThera SC for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL); RITUXAN SC for patients with CLL; and HYQVIA for the treatment of immunodeficiency disorders. In addition, it is developing Tecentriq for non-small cell lung cancer; OCREVUS for multiple sclerosis; DARZALEX for the treatment of patients with amyloidosis, smoldering myeloma, and multiple myeloma; nivolumab for the treatment of solid tumors; ARGX-113, a human neonatal Fc receptor; ARGX-117 to treat autoimmune diseases; and BMS-986179, an anti-CD-73 antibody. The company has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; Alexion Pharma Holding; ARGENX BVBA; Horizon Therapeutics plc; National Institute of Allergy and Infectious Diseases; Centre for the AIDS Programme of Research in South Africa; and ViiV Healthcare Limited for small and large molecule targets for the treatment and prevention of HIV. Halozyme Therapeutics, Inc. was founded in 1998 and is based in San Diego, California.

11388 Sorrento Valley Road
San Diego, CA 92121

CIK: 0001159036
ISIN: US40637H1095
CUSIP: 40637H109